NASDAQ · MEDICINAL CHEMICALS & BOTANICAL PRODUCTS · LARGE CAP
Tilray Brands, Inc. TLRY
9 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$821.3M
▲ 4.1% vs FY2023
EPS · FY24
—
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
-88.3%
Net margin · FY24
-266.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 821.3M
Revenue, FY2024 · full 9-year series below
Revenue
Net income
The company lost 266 cents on every revenue dollar this year.
Per share
—
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
-88.3%
Return on equity, FY2024
ROE
Operating margin-277.9%
Net margin-266.3%
Return on assets-69.5%
Each USD of equity lost 88 cents this year.
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+15.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+9.3%
+15.2%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 2.1B
total assets, end of FY2024
Total assetsUSD 2.1B
EquityUSD 1.5B
CashUSD 221.7M
Gross debtUSD 7.2M
Net debtUSD -214.5M
Current ratio2.46×
The company holds more cash than debt.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue $B
0.8
0.8
0.6
0.6
0.5
0.4
0.2
0.0
0.0
Operating income $B
−2.3
−0.2
−1.4
−0.6
−0.1
−0.1
−0.1
−0.0
−0.0
EBITDA $B
·
·
·
−0.5
−0.1
−0.1
−0.1
−0.0
−0.0
Income tax $B
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
·
·
Net income $B
−2.2
−0.2
−1.5
−0.5
−0.4
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
·
·
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−88.3
−7.2
−37.7
−10.8
−12.9
−14.2
−26.0
·
−311.8
Shares out B
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
34 of 34
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed